MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$35,621K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of short-term investm...
Stock-based compensation expense
Prepaid expenses and other asset...
Others
Negative Cash Flow Breakdown
Purchases of short-term investme...
Accrued expenses and other curre...
Operating lease liabilities
Net amortization of premiums and...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-39,702
-40,591
-42,459
-100,984
Depreciation and amortization expense
50
49
57
131
Stock-based compensation expense
4,354
4,647
2,506
7,826
Change in fair value of preferred stock tranche right liability
-
-
0
-
Net amortization of premiums and accretion of discounts on short-term investments
39
754
-1,372
2,874
Non-cash lease expense
156
151
146
415
Accounts receivable
-262
366
-15
70
Prepaid expenses and other assets
-3,143
11,046
-6,287
7,811
Accounts payable
604
-1,016
-1,226
-55
Accrued expenses and other current liabilities
-4,289
1,229
2,821
1,193
Operating lease liabilities
-160
-155
-150
-415
Net cash used in operating activities
-35,621
-47,852
-30,631
-102,644
Purchases of short-term investments
50,941
14,422
38,282
347,596
Maturities of short-term investments
66,702
56,822
97,278
195,285
Purchases of equipment
0
-
54
111
Net cash provided by (used in) investing activities
15,761
42,400
58,942
-152,422
Payments of deferred offering costs
-
-
-
34
Proceeds from the issuance of series b redeemable convertible preferred stock, net of issuance costs paid
-
-
0
-
Proceeds from exercises of stock options
-
598
907
1,372
Proceeds from issuance of common stock in connection with at-the-market offering, net of commissions
2,083
-
-
-
Proceeds from initial public offering, net of underwriters discounts and commissions
-
-
0
-
Proceeds from issuance of common stock under stock plans
1,048
-
196
-
Payments of initial public offering costs
0
0
34
-
Net cash provided by financing activities
2,533
598
1,103
1,338
Net decrease in cash, cash equivalents and restricted cash
-17,327
-4,854
29,414
-253,728
Cash, cash equivalents and restricted cash at beginning of period
96,918
101,772
72,358
326,086
Cash, cash equivalents and restricted cash at end of period
79,591
96,918
101,772
72,358
Cash and cash equivalents
79,397
-
-
-
Restricted cash
194
-
-
-
Total cash, cash equivalents and restricted cash at end of period
79,591
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of short-term
investments
$66,702K
Proceeds from issuance of
common stock in...
$2,083K
Proceeds from issuance of
common stock under...
$1,048K
Net cash provided by
(used in) investing...
$15,761K
Net cash provided by
financing activities
$2,533K
Canceled cashflow
$50,941K
Canceled cashflow
$598K
Net decrease in
cash, cash...
-$17,327K
Canceled cashflow
$18,294K
Stock-based compensation
expense
$4,354K
Prepaid expenses and
other assets
-$3,143K
Accounts payable
$604K
Accounts receivable
-$262K
Non-cash lease expense
$156K
Depreciation and
amortization expense
$50K
Purchases of short-term
investments
$50,941K
something is missing
-$598K
Net cash used in
operating activities
-$35,621K
Canceled cashflow
$8,569K
Net loss
-$39,702K
Accrued expenses and
other current...
-$4,289K
Operating lease
liabilities
-$160K
Net amortization of
premiums and accretion of...
$39K
Buy us a coffee
Upstream Bio, Inc. (UPB)
Upstream Bio, Inc. (UPB)